Hologic, Inc. / Third Wave Technologies, Inc.

Cervical Cancer / HPV Screening

$200M US HPV testing market 2008 (~$200M, 40%+ YoY growth; global potential cited at $800M)

Disease Overview

Human papillomavirus (HPV) is the primary cause of cervical cancer; high-risk strains drive precancerous lesions detected through molecular screening. Cervical cancer is largely preventable when HPV-driven dysplasia is caught early via routine screening. Molecular HPV testing is being adopted alongside or in place of traditional Pap cytology in women's health screening.

Competitive Landscape

In 2008, the US HPV testing market was dominated by Qiagen's Digene Hybrid Capture 2 (HC2) — the only FDA-approved high-risk HPV DNA test at the time — which controlled essentially all of the ~$200M US market that was growing >40% annually. Roche Diagnostics (cobas HPV, later FDA-approved 2011) and Gen-Probe (Aptima HPV mRNA, FDA-approved 2011) were developing competing platforms. Third Wave's Cervista HR HPV and Cervista HPV 16/18 — built on its proprietary Invader chemistry — had PMAs filed with the FDA at the time of the Hologic deal and were positioned as the first credible US challenger to Qiagen's Digene franchise. Hologic's strategic logic was vertical integration: it already controlled the ThinPrep liquid-based cytology workflow that pathology labs used for Pap testing, so adding Cervista let it sell co-tested cervical cancer screening as a bundled offering and capture wallet share Qiagen could not match. Cervista received FDA approval in March 2009, becoming the second HPV test cleared in the US. The deal reshaped women's health diagnostics by creating a pure-play screening franchise (ThinPrep + Cervista + later Aptima after the 2012 Gen-Probe acquisition) competing head-on with Qiagen.